Calquence approved in the EU for the treatment of chronic lymphocytic leukaemia
9 November 2020 07:00 GMT Calquence approved in the EU for thetreatment of chronic lymphocytic leukaemia Calquence demonstrated superior progression-free survival and favourable tolerability in both previously untreated and relapsed or refractory patients AstraZeneca's Calquence (acalabrutinib), a next-generation selective Bruton's tyrosine kinase (BTK) inhibitor, has been approved in the European Union (EU) for the treatment of adult patients with chronic lymphocytic leukaemia (CLL), the most common type of leukaemia in adults. The approval by the European Commission was